Warning has been added to the Prescribing Information of Tysabri (Natalizumab)
2008-03-05
February 29, 2008 – The U.S Food and Drug Administration (FDA), the equivalents of the Saudi Food and Drug Authority (SFDA), announced that the Biogen ldec and Elan the manufacturer of TYSABRI" (natalizumab),a medicine used to treat patients with relapsing forms of multiple sclerosis (MS) to reduce the number of relapses, has notified healthcare professionals that the full Prescribing Information has been revised to add to the Warnings and Precautions section informatio